Health Condition 1: null- Dementia with Lewy bodies and Parkinsons Disease with Dementia
Conditions
Interventions
Intervention1: Active transcranial direct current stimulation (tDCS): 1 x 20 minute session of active 2.8mA transcranial direct current stimulation (tDCS) delivered to the left dorsolateral prefrontal
50% between F3 and FP1 on the basis of the International 10-20 system)
Control Intervention1: Placebo transcranial direct current stimulation (tDCS): 1 x 20 minute session of placebo 2.8mA transcrania
50% between F3 and FP1 on the basis of the International 10-20 system)
Sponsors
Institute of Neurosciences Kolkata
Eligibility
Inclusion criteria
Inclusion criteria: Participants are required to Have been stable on anti-cholinesterase, anti-psychotic, memantine and/or anti-parkinsonian medication for at least one month prior to participation. Be able to provide written, informed consent Be free from concurrent major psychiatric illness (e.g. major depression). Be free from any severe physical illness or co-morbidities which might limit their ability to fully participate in the study, or influence the effects of tDCS.
Exclusion criteria
Exclusion criteria: Participants will be unable to take part if any of the following apply: If they have skin allergies or sensitivities to electrode gels, or any significant dermatological / scalp disease. A history of excess alcohol intake. A history of moderate-to-severe visual impairment secondary to glaucoma, cataract, or macular degeneration. If they have metallic implants in the head/neck area or electronic implants of any kind (including pacemakers). If they have a history of other neurological illness including, but not limited to stroke, intracerebral pathology and epilepsy. If they are currently taking psychotropic or other medications which may significantly interfere with cognitive testing and tDCS efficacy (including high dose antipsychotics, dopamine agoinsts, sedative antidepressants, benzodiazepines except when low dose and used as hypnotics or treatment for REM-sleep behaviour disorder and centrally acting anticholinergic drugs).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Four computerised attentional tasks: Simple reaction time; Choice reaction time; Digit Vigilance; Modified Attentional Network Task. Timepoint: Time 1 and Time 2 (between 24 hours and one week after Time 1) | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicableTimepoint: Not applicable | — |
Countries
India
Contacts
Public ContactDr Hrishikesh Kumar
Outcome results
None listed